No Access
A high-dose, double-blind study of ceruletide in the treatment of schizophrenia
Published Online:1 Apr 2006https://doi.org/10.1176/ajp.142.12.1482
Abstract
Ceruletide, a cholecystokinin analogue, has been reported to interact with dopamine in the CNS and to benefit schizophrenic individuals. The authors, using a double-blind design, a higher total dose, and a larger sample size than previous studies, found no evidence of benefit.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
